[ad_1]
Burjeel Medical City has been selected as a member of the Global Innovation Network (WIN) Alliance for Personalized Cancer Medicine.
The achievement marks another major milestone for the healthcare provider as it continues to expand its network and expertise in oncology and further cements its position as a pioneer in personalized cancer medicine in the United Arab Emirates and the wider region.
Burjeel Medical City has now become the first member from the UAE and GCC countries to join this prestigious network and will act as an accelerator to facilitate further regional collaborations in WIN programs and projects.
30 elite organizations
The WIN Alliance is a globally renowned network of more than 30 elite organizations specialized in cancer care and research from the Americas, European Union and Asia. These represent the various stakeholders involved in the patient journey and personalizing cancer care. The primary goal of the alliance is to improve the survival and quality of life of cancer patients through genetic information-dependent healthcare and to accelerate the discovery and development of highly specialized cancer therapies.
Becoming a member of the WIN Alliance is a major milestone for Burjeel Medical City, which aims to become a regional center for cancer care, continuously accelerating research and innovation programmes. By joining this exclusive expert network, the hospital strengthens its commitment to developing targeted cancer therapies, strategically aligned with WIN’s mission.
“We are honored to join the WIN Alliance, which is at the forefront of personalized cancer medicine research. Through this membership, we further our commitment to advancing the understanding and treatment of cancer in the era of personalized care by partnering with elite global teams. The WIN Alliance is We provide a unique platform to share knowledge, expertise and data to accelerate the development of innovative solutions and new therapies,” said Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.
Personalized Cancer Medicine
Richard L Schilsky MD, FACP, FSCT, FASCO, Principal Investigator of the ASCO TAPUR study, Professor Emeritus at the University of Chicago and Chairman of the WIN Consortium, said: “Burjeel Medical City’s expertise and resources in oncology and the scale of the Group’s operations in the Middle East It will be invaluable to our collaborative research efforts to advance personalized cancer medicine globally.”
The hospital is a member of the WIN Consortium, which will be represented by Professor Humaid Al Shamsi, Burjeel Holdings Director of Oncology Services, and Dr Khaled Musallam, Burjeel Holdings Group Chief Research Officer, a testament to its commitment to delivering excellence in care and advancing the field of oncology. — trade arab news agency
[ad_2]
Source link